Oman vs Sur: Previously treated cases tested for RR-/MDR-TB
Oman
100.0%
in 2024
Sur
62.0%
in 2024
Oman rank
1st
Sur rank
1st
Previously treated cases tested for RR-/MDR-TB over time
- Oman
- Sur
How they compare
Oman currently reports 100.0% against 62.0% in Sur, a difference of 38.0%.
That makes Oman's figure about 1.6 times Sur's.
The two have swapped places 2 times across 16 shared years of data; in 2005 it was Oman ahead.
Oman ranks 1st and Sur ranks 1st of 180 countries.
Oman has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Oman | Sur | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 100.0% | 14.3% | 85.7% | Oman |
| 2010s | 97.8% | 53.0% | 44.8% | Oman |
| 2020s | 100.0% | 76.0% | 24.0% | Oman |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Oman or Sur?
- Oman, at 100.0% against 62.0% in Sur as of 2024.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Oman and Sur?
- 38.0%, with Oman ahead.
- How many years of comparable data are there for Oman and Sur?
- 16 years are reported by both, from 2005 to 2024.
- How do Oman and Sur rank globally for previously treated cases tested for rr-/mdr-tb?
- Oman ranks 1st and Sur ranks 1st of 180 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.